515 related articles for article (PubMed ID: 23796475)
1. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
[TBL] [Abstract][Full Text] [Related]
4. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation.
Lin Y; Yang X; Liu W; Li B; Yin W; Shi Y; He R
Oncogene; 2017 Jun; 36(25):3599-3608. PubMed ID: 28166197
[TBL] [Abstract][Full Text] [Related]
5. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
[TBL] [Abstract][Full Text] [Related]
7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
9. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Cao M; Xu Y; Youn JI; Cabrera R; Zhang X; Gabrilovich D; Nelson DR; Liu C
Lab Invest; 2011 Apr; 91(4):598-608. PubMed ID: 21321535
[TBL] [Abstract][Full Text] [Related]
11. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function.
Hu CE; Gan J; Zhang RD; Cheng YR; Huang GJ
Scand J Gastroenterol; 2011 Feb; 46(2):156-64. PubMed ID: 20822377
[TBL] [Abstract][Full Text] [Related]
12. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
14. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
15. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F
Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857
[TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
18. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
19. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Groß C; Steiger K; Sayyed S; Heid I; Feuchtinger A; Walch A; Heß J; Unger K; Zitzelsberger H; Settles M; Schlitter AM; Dworniczak J; Altomonte J; Ebert O; Schwaiger M; Rummeny E; Steingötter A; Esposito I; Braren R
Clin Cancer Res; 2015 Oct; 21(19):4440-50. PubMed ID: 25995341
[TBL] [Abstract][Full Text] [Related]
20. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.
Jayaraman P; Parikh F; Lopez-Rivera E; Hailemichael Y; Clark A; Ma G; Cannan D; Ramacher M; Kato M; Overwijk WW; Chen SH; Umansky VY; Sikora AG
J Immunol; 2012 Jun; 188(11):5365-76. PubMed ID: 22529296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
